Please login to the form below
Oligomannate
This page shows the latest Oligomannate news and features for those working in and with pharma, biotech and healthcare.
China okays Green Valley’s algae-based drug for Alzheimer’s drug
Oligomannate is the first new drug to be approved for Alzheimer’s since memantine, which was approved in Europe in 2002 and the US in 2003. ... Green Valley says it will launch Oligomannate in China 'very soon' while also carrying out trials to
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- How COVID-19 is accelerating the threat of antimicrobial resistance
- 20 for 2020 – Five pharma companies to watch
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
